Food and Drug Administration (FDA) vaccine advisors today recommended that the agency grant emergency use authorization (EUA) for Johnson & Johnson’s COVID-19 vaccine, which brings the nation one step closer to having a third COVID-19 vaccine. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) was asked to consider if the benefits outweigh the risks in people ages 18 and older. The measure passed unanimously, with 22 affirmative votes. After the vote, Archana Chatterjee, MD, PhD, a VRBPAC member who is a pediatric infectious disease specialist and dean of Chicago Medical School, said despite concerns raised during today’s discussion, it’s good to keep in mind that the world is still in a pandemic. “This vaccine will help meet the needs at the moment.” Members also said the nation is in a race against mutated viruses and stopping the spread of the virus. They also said the Johnson & Johnson vaccine clears well above the bar as a good vaccine and that none are recommended as better than the others. They also said they hoped for more data, which will help guide clinical use.

 

Read more CIDRAP…